Video

Dr. Hurvitz on the Clinical Use of Biosimilars in Oncology

Author(s):

Sara A. Hurvitz, MD

In Partnership With:

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical use of biosimilars in oncology.

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses the clinical use of biosimilars in oncology.

As of 2018, the only biosimilar that is being used in clinical practice in the US is the filgrastim (Neupogen) biosimilar. Hurvitz says that she gives her patients the biosimilar of filgrastim, as it is a more affordable version, and it has met the biosimilarity criteria required by the FDA.

Biosimilars for trastuzumab (Herceptin) and bevacizumab (Avastin) have been FDA approved, but the originator drugs are not yet off patent, so they are not available in the US for clinical use. Moreover, there is pending litigation regarding the patents, so it may be a few years before these biosimilars are used in the US as a treatment for cancer, Hurvitz concludes.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT
December 13th 2024

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine
August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

Aditya Bardia, MD, MPH, FASCO, of UCLA
October 15th 2024

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Paolo Tarantino, MD
September 26th 2024

Breast Cancer Experts Spotlight Early-Phase and Real-World Research at the 2024 ESMO Congress

Adam E. Singer, MD, PhD, of UCLA Health
September 13th 2024

Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care